Use of E-Selectin Tolerization as Treatment for Immunological and Vascular-Related Disorders
This technology relates to the mucosal delivery (e.g. intranasal) of an E-selectin fragment as a tolerization agent for the prevention and treatment of immunological and vascular-related disorders, including stroke and multiple sclerosis (MS) as well as rare or orphan diseases involving vascular modulated disorders.
E-selectin is an adhesion molecule that is expressed on endothelial cells lining blood vessels in response to certain localized cytokines, making the endothelial surface pro-coagulant, pro-inflammatory and/or immunoreactive. Such changes on the endothelial surface have been linked to the development of vascular-related disorders like stroke, as well as immune regulated diseases such as MS.
Intranasal administration of E-selectin, using a tolerizing dosing schedule, induces an immunological tolerance to E-selectin. T regulatory cells become targeted to activating blood vessel segments, where they release immunomodulatory cytokines such as IL-10. This release of cytokines suppresses local pro-coagulant, pro-inflammatory and immunoreactive effects. Thus, administration of E-selectin as a tolerizing agent will provide a targeted therapeutic approach, impacting only affected sites in the endothelium.
IC: NINDSNIH Ref. No.: E-237-1999/0TAB No: TAB-440Advantages: Low doses utilized thus minimizing potential side effects.
Animal data are available, with further studies currently on-going.
Administration through the intranasal route represents a les...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: admin Source Type: research
More News: Allergy & Immunology | Arthritis | Autoimmune Disease | Diabetes | Diabetes Type 1 | Endocrinology | Multiple Sclerosis | Neurology | Psoriasis | Research | Rheumatoid Arthritis | Rheumatology | Stroke | Study